NEJM Evidence · 2023 · 45 citations · 17 references
MedicineImmunologyPediatricsHypersensitivityImmunotherapyPediatric AllergyAllergen ImmunotherapyFood AllergensFood AllergyOral Food ChallengePeanut AllergyPediatric Food AllergiesDouble-blind Placebo-controlled Food ChallengeDouble-blind TrialsFood Allergy Tolerance AssessmentFood Oral ImmunotherapyMedication-related Adverse EventsPeanut Food ChallengePlacebo ComparatorsPlacebo-controlled Efficacy Assessment
BACKGROUND: Peanut allergy is a common childhood allergy, and the only approved treatment for children 4 to 17 years of age is peanut allergen powder-dnfp (PTAH) oral immunotherapy. METHODS: For this phase 3, randomized, double-blind, placebo-controlled trial, we enrolled peanut-allergic children 1 to <4 years of age who experienced dose-limiting symptoms from ≤300 mg peanut protein during a screening double-blind, placebo-controlled food challenge (DBPCFC). Participants received PTAH or placebo, randomized in a 2:1 ratio, for approximately 12 months. At the trial conclusion, all participants underwent an exit BDPCFC. The primary end point was desensitization (i.e., tolerating a ≥600-mg single dose of peanut protein with only mild allergy symptoms). RESULTS: In the PTAH-treated group (n=98), 73.5% of participants tolerated a single dose of ≥600 mg peanut protein at exit DBPCFC compared with 6.3% in the placebo group (n=48). Most participants experienced an adverse event (98.0% of PTAH-treated and 97.9% of placebo-treated participants), which was mild or moderate in grade for 93.2% of participants (92.9% in PTAH-treated and 93.8% in placebo-treated participants). Treatment-related adverse events, which were mild to moderate, were experienced by 75.5% of PTAH-treated and 58.3% of placebo-treated participants. Three treatment-related systemic allergic reactions, none of which were severe or serious in grade, were noted in two PTAH-treated participants (2%). CONCLUSIONS: In peanut-allergic children 1 to <4 years of age treated with PTAH for approximately 12 months, the majority tolerated all peanut protein dose levels assessed. PTAH-treated patients had more treatment-related adverse events, which were mild to moderate severity. (Funded by Aimmune Therapeutics; ClinicalTrials.gov number, NCT03736447.)
17
Hugh A. Sampson, Anne Muñoz‐Furlong, Ronna L. Campbell et al. · Journal of Allergy and Clinical Immunology · 2006 · 2.3K citations
Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy
George Du Toit, Graham Roberts, Peter H. Sayre et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text
Medicine, Child Health, Pediatrics +13
AR101 Oral Immunotherapy for Peanut Allergy
New England Journal of Medicine · 2018 · 745 citations · Full text
Oral Immunotherapy for Treatment of Egg Allergy in Children
A. Wesley Burks, Stacie M. Jones, Robert A. Wood et al. · New England Journal of Medicine · 2012 · 699 citations · Full text